Journal of Innovations in Applied Pharmaceutical Science [JIAPS]

Content available at: www.saap.org.in ISSN: 2455-5177

QUALITY BY DESIGN IN PHARMACEUTICALS: ENHANCING PRODUCT DEVELOPMENT AND REGULATORY COMPLIANCE

CHILAKA YOGITHA, CHINTHAPALLI DEEKSHITHA, KANNAPADUTULA AASHRITHA, MIRIYAPPALLI SRAVANI, DARAPU SWETHA, MADDI RAMAIAH

Maharajah's College of Pharmacy, Phool Baugh, Vizianagaram, A.P – 535002, India.

DOI: https://doi.org/10.37022/jiaps.v11i2.827

Article History

Received: 24-02-2026
Revised: 18-03-2026
Accepted: 16-04-2026

Keywords: *QbD; pharmaceutical development; drug product quality; quality risk management; critical quality attributes; quality target product profile; approaches of QbD.*

***Corresponding Author**

Dr. Ramaiah Maddi

Abstract

Quality by Design represents a methodical and scientific strategy in pharmaceutical development, emphasizing the integration of quality into products from the outset instead of depending exclusively on testing the final product. This article highlights the key principles of Quality by Design (QbD), which include creating a Quality Target Product Profile (QTPP) and identifying Critical Quality Attributes (CQAs) and using risk assessment tools to ensure product consistency and safety. It also emphasizesthe significance of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) in affecting product quality. Advanced techniques such as Design of Experiments (DoE) and Process Analytical Technology (PAT) are discussed to optimize formulations and assist real-time observation throughout the manufacturing process. The concept of design space along with the formulation of efficient control strategies are highlighted as essential components for attaining regulatory flexibility and reliable processes. Additionally, the article examines the utilization of Quality by Design (QbD) in product development and manufacturing, analytical method development, and lifecycle management. Overall, QbD enhances product quality, reduces variability, minimizes failures, and supports continuous improvement, making it a vital approach in modern pharmaceutical industries.

1. INTRODUCTION

Quality by Design (QbD) represents a methodical strategy in pharmaceutical development that initiates with clearly defined objectives and prioritizes the comprehension and regulation of both product and process, grounded in robust scientific principles and effective quality risk management [1-2]. It utilizes tools such as QTPP, CQAs, risk analysis, DoE, design space, PAT, and control strategy.

An essential component of Quality by Design (QbD) involves recognizing the elements that affect product quality, including Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs) [3-4]. By understanding how these variables interact, researchers can design robust processes that minimize variability and enhance product performance. The utilization of tools such as Design of Experiments (DoE) and Process Analytical Technology (PAT) enhances optimization and facilitates real-time monitoring, thereby ensuring improved control over manufacturing results.

In addition to improving product quality, QbD offers several advantages in terms of regulatory compliance and operational efficiency. Regulatory authorities encourage its adoption as it provides a scientific basis for decision-making and allows flexibility within an established design space. This approach also facilitates continuous improvement throughout the product lifecycle, making it highly relevant in the context of modern pharmaceutical development [5-6].

This review article seeks to deliver an extensive summary of the principles, tools, and applications of Quality by Design (QbD) within the pharmaceutical sector. It emphasizes the significance of implementing a systematic methodology to ensure consistent product quality, reduce risks, and improve overall process comprehension [7-8].



Figure 01: - Elements of QbD

Key features are

- Established goals (target product profile)
- Comprehension of the process and formulation
- Recognition of critical quality attributes (CQAs)
- Evaluation and management of risks
- Creation of design space
- Strategy for control
- Ongoing enhancement throughout the product lifecycle [9]

2. LITERATURE SEARCH STRATEGY & SELECTION CRITERIA

A structured literature search was performed using databases such as PubMed, Google Scholar, Scopus to identify studies related to Quality by Design. Keywords including "QbD", "Pharmaceutical Development", "Drug Product Quality", "Quality Rik Management" were used. Articles published between 2013 to 2025 were considered. Relevant peer-reviewed research articles and reviews focusing on QbD approaches, uses, applications, steps involved were included, while duplicate records and unrelated studies were excluded.

3. APPROACHES OF QbD

3.1. Target Product Profile

It describes the intended use, safety, and efficacy of the drug product

- Comprises the dosage form, strength, route of administration, and therapeutic goals
- It acts as the foundation for product development [9]

3.2 Identify Critical Quality Attributes

- Critical Quality Attributes (CQAs) encompass physical, chemical, biological, or microbiological characteristics that require regulation [10]
- Ensures that the product adheres to the required quality standards.

3.1. Risk Assessment

- Identifies potential risks affecting product quality [11].
- Tools used
  - Failure mode and effects analysis
  - Ishikawa (Fishbone) diagram
  - Hazard Analysis and Critical Control Point
- Helps prioritize critical factors

3.2. Identify Critical Material Attributes & Critical Process Parameters

- CMAs:- properties of raw materials (e.g.: particle size purity)
- CPPs:- process variables (e.g. Temperature, mixing time)
- These factors directly influence CQAs [12-13].

3.3. Design of Experiments (DoE)

- A statistical technique to study the effect of multiple variables
- Helps in: optimization of formulation & Understanding interactions [14].
- Types: - factorial design and response surface design

3.4. Establish design space

- Characterized as a multidimensional spectrum of factors that guarantees product quality [15].
- Functioning within this domain ensures reliable performance
- Offers regulatory adaptability

3.5. Process Analytical Technology

- Continuous observation of critical quality and process parameters [16].
- Ensures quality throughout the manufacturing process rather than solely post-production
- Aids in minimizing defects and enhancing efficiency

3.6. Control Strategy

- Planned a set of controls to maintain product quality [17].
- It includes: - raw materials, in-process controls, finished product testing

3.7. Product Lifecycle Management

- Continuous monitoring and improvement throughout product life
- It includes: - change management,
- CAPA (Corrective Action and Preventive Action) [18].
- Ensures long-term quality and performance

3.8. Continuous Improvement

- Data collected during manufacturing is used to improve productivity enhancement and product quality [19].
- Ensures robust and reliable pharmaceutical products

2. USES OF QbD IN PHARMACEUTICAL INDUSTRY

3.1. Ensures consistent product quality

- QbD helps in developing pharmaceutical products with consistent and reproducible quality
- By identifying and controlling CQAs, the variability in product performance is minimized [20].
- Ensures uniformity in properties like dissolution, content uniformity, and stability [21].

3.2. QbD provides a deep understanding

- Relationship between formulation variables and product quality
- Impact of process parameters on final output
- This scientific understanding helps in designing robust and reliable manufacturing processes

3.3. Reduction in batch failures and rejections

- Traditional methods depend on end product testing, which may lead to batch rejection [22].
- QbD minimizes failures by: -
- Identifying risks easily
- Controlling critical variable

3.4. Effective risk management

QbD incorporates Quality Risk Management (QRM) principles:

- Identifies potential risks affecting quality
- Uses tools like :-
  - Failure mode and effects analysis
  - Ishikawa (fishbone) diagram
  - Hazard analysis and critical control points
- This ensures proactive risk control rather than reactive control [23].

3.5. Optimization of formulation & Manufacturing process

- QbD uses Design of Experiments to: -
  - Examine various factors concurrently
  - Optimize formulation composition & process [24].
- Results in improved efficiency & product performance

3.6. Establishment of design space

- The design space encompasses the range of process parameters and material characteristics that guarantee product quality.
  - Benefits: -
  - ➢ Flexibility in manufacturing
  - ➢ Ability to make changes without regulatory approval
  - Ensures consistent product output

3.7. Application of Process Analytical Technology

- PAT allows real-time monitoring & control of manufacturing processes [24].
  - Helps in:
  - ➢ Detecting variations instantly
  - ➢ Ensuring quality during production
  - Reduces dependence on final product testing

3.8. Regulatory advantages

- Regulatory agencies like ICH & USFDA encourage QbD approach [26].
  - Leads to: -
  - ➢ Faster approval of drug applications
  - ➢ Reduced regulatory queries
  - ➢ Easier handling of post-approval changes
- Makes the regulatory process more science & risk based

3.9. Reduction in cost & time

- Minimizes product recalls, batch failures, and wastage of materials.
- Improves manufacturing efficiency & resource utilization
- Ultimately reduces production cost & development time 27].

3.10. Life cycle management & Continuous improvement

- QbD supports continuous monitoring throughout the product lifecycle [28].
- Data collected during manufacturing is analyzed
- Used for:
  - ➢ Process improvement
  - ➢ Corrective & preventive actions (CAPA)
  - Ensures sustained product quality over time

3.11. Improved manufacturing robustness

- QbD helps develop robust processes that can tolerate small variations [29].
- Ensures stable performance even under variable conditions

3.12. Better customer safety & satisfaction

- Ensures delivery of safe, effective, & high-quality medicines
- Reduces chances of product defects & therapeutic failure

3. APPLICATIONS

3.1. Pharmaceutical Product Development

Quality by Design (QbD) is employed to guarantee that a pharmaceutical product achieves defined clinical performance objectives by recognizing and managing variables at an early stage [30]. Formulation Optimization: Identifying the Quality Target Product Profile to define desired drug characteristics (e.g., dosage form, stability) [31]. Design of Experiments: Using statistical tools to study multiple factors simultaneously, reducing the number of trial-and-error experiments by 30–50%. Risk Assessment: Utilizing tools like Ishikawa (Fishbone) diagrams and FMEA (Failure Mode and Effects Analysis) to prioritize critical material attributes (CMAs) like particle size or excipient type.

3.2. Manufacturing and Process Control

- QbD transforms manufacturing from "fixed" to "flexible" processes within a defined Design Space. (Lee et al.,2022)
- Process Understanding: Identifying Critical Process Parameters-temperature, stirring speed, or homogenization time-that significantly impact final quality.
- Continuous Manufacturing: Supporting real-time adjustments and monitoring through Process Analytical Technology (PAT), which uses sensors like NIR or Raman spectroscopy.
- Scale-Up and Tech Transfer: Establishing science-based operating ranges that make transitioning from lab-scale to commercial-scale production more predictable, reducing batch failures by up to 40%.

3.3. Analytical Method Development (AQbD)

- Applying QbD to laboratory testing (Analytical Quality by Design) ensures that methods are robust and reliable throughout their lifecycle.
- Chromatographic Methods: Optimizing HPLC and GC methods by defining an Analytical Target Profile (ATP) to ensure accurate quantification of compounds.
- Real-Time Release Testing: Enabling the release of batches relying on ongoing data instead of postponing for extensive final product evaluations.

3.4. Specialized Delivery Systems

- QbD is increasingly applied to complex and modern drug delivery platforms [32].
- Nano-pharmaceuticals: Precise control of particle size, zeta potential, and drug loading in liposomes, nanoparticles, and nanosuspensions.
- Biopharmaceuticals: Managing variability in fermentation, purification, and cell culture conditions to ensure consistent protein stability and yield.

3.5. Regulatory and Business Benefits

- Regulatory Flexibility: Manufacturers can implement process improvements within the approved design space without requiring new regulatory filings for each change [33].
- Cost and Waste Reduction: Minimizing out-of-specification (OOS) batches and rework, leading to faster time-to-market and lower production costs.

3.6. Generic drug development (ANDA)

Demonstrating equivalence, robustness & consistent performance of generic drugs to regulatory bodies, often reducing review times [34].

3.7. Analytical method development

Designing robust testing methods. e.g.: HPLC, which are fit for purpose, minimizing the need for method revalidation [35].

Manufacturing Efficiency

Reduces wastage and rework Improves productivity Ensures cost-effective production [36].

3.8. Dissolution & Drug release optimization

QbD helps in improving drug release profiles. Controls dissolution rate (important for tablets like extended-release forms) ensures consistent therapeutic effect [37].

5.10 Continuous improvement

In Pharma Industry Ongoing monitoring and process improvement Reduces production cost and increases efficiency Supports lifecycle management of drugs [38].

5.11 Scale-up & Technology transfer helps in transferring process from lab in industry

Maintains product quality during large-scale production [39].

5.12 Regulatory compliance

Supported by US Food and Drug Administration (USFDA) and International Council for Harmonization (ICH) provides strong scientific data for approvals allows flexibility within design space [40].

STEPS

3.10. Establish the Analytical Target Profile

This is where you define what your analytical method will accomplish. This step establishes the key elements that define your methods' requirements [41].

These include:

The purpose of the method (i.e. what you are measuring and why); and, the performance criteria of your method including; accuracy, precision, sensitivity, specificity, etc.

33.10. Risk Assessment

Risk assessments identify the most likely variables that could affect your analytical methods ability to perform at its best. Variables identified through a risk assessment can then be assigned priority based on their likelihood of occurrence [41]. Failure Mode and Effects Analysis (FMEA) allow you to determine which risks need to be mitigated first.

3.10. Establish Critical Quality Attributes & Critical Method Parameters

- Critical Quality Attributes are those aspects of your analytical method that MUST be controlled to ensure that you produce high-quality data [42]. Examples of these attributes include: retention time; resolution; etc.
- Critical Method Parameters (CMP) are factors that can potentially effect CQA. These include: pH; temperature; flow rates; etc.

3.10.Design of Experiments (DoE)

- Design of Experiments is a structured way of performing experiments. In this case it involves:
- Identifying variables: select the variables that have been determined to pose a risk to your analytical methods performance, based on the prior risk assessment [43-49].
- Designing an experimental matrix: organize your experiments so that you can evaluate how the interaction between variables affects CQAs.
- Evaluating data: use statistical methods to assess how each variable impacts each CQA.

3.10. Development & Optimization of Your Method

- Use the information obtained from DoE to refine and improve your analytical method emphasize-
- Robustness: verify that your analytical method produces consistent results over different conditions.
- accuracy and precision: confirm whether your analytical method accurately measures concentrations of analyte(s) [50-55].

3.10.Validation of Your Method

- Validation ensures that your analytical method meets all the specifications outlined by the ATP. The minimum required validations include:
- Linearity: demonstrate that the output from your method is linearly related to the input (concentration of analyte(s).
- Precision: confirm that repeated analyses under constant conditions give similar results.
- Accuracy: validate that measured values are close to the true values.
- Specificity: confirm that your analytical method can selectively measure analyte(s) in the presence of other substances.
- Sensitivity: establish the limits of detection and quantitation [59-58].

6.7 Ongoing monitoring & Enhancement

Once the method has been validated and implemented, continuous monitoring is crucial. Gather data to guarantee sustained compliance with the ATP and implement improvements as needed.



Figure 02: Steps involved in QbD [59]

4. CONCLUSION

Quality by Design embodies a contemporary and methodical strategy for pharmaceutical development, integrating quality into the product from the outset instead of evaluating it solely at the conclusion. By identifying and controlling key factors such as Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs), QbD ensures consistent product quality and minimize variability in manufacturing.

The application of scientific tools like Design of Experiments and Process Analytical Technology enables better understanding, optimization, and real-time monitoring of processes. This not only improves efficiency but also minimizes the chances of batch failures and product recalls. Additionally, the concept of design space and control strategy provides flexibility in operations while maintaining regulatory compliance.

Overall, QbD enhances product reliability, supports continuous improvement, and aligns with current regulatory expectations. Its adoption plays an essential function in providing secure, efficient, and high-quality pharmaceutical products, making it an essential approach in the evolving pharmaceutical industry.

5. ACKNOWLEDGEMENT

Not Declared

6. FUNDING

Nil

7. CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

8. INFORM CONSENT AND ETHICAL CNSIDERATIONS

Not applicable

9. AUTHOR CONTRIBUTIONS

Both are contributed equally.

10. REFERENCES

1. Mishra V, Thakur S, Patil A, Shukla A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin Drug Deliv. 2018;15(8):737-758. doi:10.1080/17425247.2018.1504768.
2. Namjoshi S, Dabbaghi M, Roberts MS, Grice JE, Mohammed Y. Quality by design: development of the quality target product profile (QTPP) for semisolid topical products. Pharmaceutics. 2020;12(3):287. doi:10.3390/pharmaceutics12030287.
3. Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44(5):291-305.
4. Kelley B, Cromwell M, Jerkins J. Integration of QbD risk assessment tools and overall risk management. Biologicals. 2016;44(5):341-351.
5. Rege PD, Schuster A, Lamerz J, Moessner C, Göhring W, Hidber P, et al. QbD approach to process characterization and quantitative criticality assessment of process parameters. Org Process Res Dev. 2024;28(3).
6. Benetti C, Benetti AA. Quality by design in formulation development. In: Introduction to Quality by Design (QbD) from Theory to Practice. Singapore: Springer Nature Singapore; 2024. p. 139-159.
7. Fukuda IM, Pinto CF, Moreira CD, Saviano AM, Lourenço FR. Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Braz J Pharm Sci. 2018;54:e01006.
8. Mishra V, Thakur S, Patil A, Shukla A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin Drug Deliv. 2018;15(8):737-758.
9. Calhan SD, Eker ED, Sahin NO. Quality by design (QbD) and process analytical technology (PAT) applications in pharmaceutical industry. Eur J Chem. 2017;8(4):430-433.
10. Kepert JF, Cromwell M, Engler N, Finkler C, Gellermann G, Gennaro L, et al. Establishing a control system using QbD principles. Biologicals. 2016;44(5):319-331.
11. Verch T, Campa C, Chery CC, Frenkel R, Graul T, Jaya N, et al. Analytical quality by design, life cycle management, and method control. AAPS J. 2022;24(1):34.
12. Beg S, Hasnain MS, Rahman M, Swain S. Introduction to quality by design (QbD): fundamentals, principles, and applications. In: Pharmaceutical Quality by Design. Academic Press; 2019. p. 1-17.
13. Patil AS, Pethe AM. Quality by design (QbD): a new concept for development of quality pharmaceuticals. Int J Pharm Qual Assur. 2013;4(2):13-19.
14. Lee SH, Kim JK, Jee JP, Jang DJ, Park YJ, Kim JE. Quality by design (QbD) application for the pharmaceutical development process. J Pharm Investig. 2022;52(6):649-682.
15. Jain S. Quality by design (QbD): a comprehensive understanding of implementation and challenges in pharmaceuticals development. Int J Pharm Pharm Sci. 2014;6(1):29-35.
16. Volta e Sousa L, Gonçalves R, Menezes JC, Ramos A. Analytical method lifecycle management in pharmaceutical industry: a review. AAPS PharmSciTech. 2021;22(3):128.
17. Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J. Pharmaceutical product development: a quality by design approach. Int J Pharm Investig. 2016;6(3):129-138.
18. Ameen SA, Pappula N. Analytical QbD approach to redefine the quality of pharmaceuticals: a review. J Pharm Res. 2023;22(4):179.
19. Mohseni-Motlagh SF, Dolatabadi R, Baniassadi M, Baghani M. Application of the quality by design concept (QbD) in the development of hydrogel-based drug delivery systems. Polymers. 2023;15(22):4407.
20. Vishwasrao SS, Singh S. Current perspective on opportunities and adoption challenges of QbD implementation in pharmaceutical product development. Pharm Process Dev. 2016;33:34-41.
21. Hasan M, Shimu S, Akther A, Jahan I, Hamiduzzaman M, Hasan AH. Development of generic drug products by pharmaceutical industries considering regulatory aspects: a review. J Biosci Med. 2021;9(10):23-39.
22. Thakur D, Kaur A, Sharma S. Application of QbD based approach in method development of RP-HPLC for simultaneous estimation of antidiabetic drugs in pharmaceutical dosage form. J Pharm Investig. 2017;47(3):229-239.
23. Sousa AS, Serra J, Estevens C, Costa R, Ribeiro AJ. A quality by design approach in oral extended-release drug delivery systems: where we are and where we are going? J Pharm Investig. 2023;53(2):269-306.

24. Duarte JG, Duarte MG, Piedade AP, Mascarenhas-Melo F. Rethinking pharmaceutical industry with quality by design: application in research, development, manufacturing, and quality assurance. AAPS J. 2025;27(4):96.
25. Ahmend SU, Katdare A, Naini V, Wadgaonkar D. Scale-up, technology transfer, and process performance qualification. In: Generic Drug Product Development: Solid Oral Dosage Forms. 2014. p. 129.
26. Furlanetto S, Orlandini S, Pieraccini G, Gotti R, Massolini G, Temporini C, et al. Analytical quality by design and quality control of drugs: from quality target product profile to the analytical target profile. In: Book of Abstracts 29th International Symposium on Electro- and Liquid-Phase Separation Techniques-ITP 2023; 2023. p. 70.
27. Tiwari R, Mahalpure GS, Tyagi S, Dahiya M, Kalaiselvan V. Analytical quality by design (AQbD) for quality and risk assessment of pharmaceuticals to immunomarkers. J Pharm Biopharm Res. 2025;7(1):511-524.
28. Politis S. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017.
29. Tome T, Žigart N, Časar Z, Obreza A. Development and optimization of liquid chromatography analytical methods by using AQbD principles: overview and recent advances. Org Process Res Dev. 2019;23(9):1784-1802.
30. Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43(6):889-901. doi:10.1080/03639045.2017.1291672.
31. Mishra V, Thakur S, Patil A, Shukla A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin Drug Deliv. 2018;15(8):737-758. doi:10.1080/17425247.2018.1504768.
32. Li M, Zhao X, Yu C, Wang L. Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy. Pharm Res. 2024;41(3):419-440. doi:10.1007/s11095-023-03649-z.
33. Pedro F, Veiga F, Mascarenhas-Melo F. Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: how obvious is it? Drug Discov Today. 2023;28(11):103759. doi:10.1016/j.drudis.2023.103759.
34. Duarte JG, Duarte MG, Piedade AP, Mascarenhas-Melo F. Rethinking pharmaceutical industry with quality by design: application in research, development, manufacturing, and quality assurance. AAPS J. 2025;27(4):96. doi:10.1208/s12248-025-01079-w.
35. Volta E Sousa L, Gonçalves R, Menezes JC, Ramos A. Analytical method lifecycle management in pharmaceutical industry: a review. AAPS PharmSciTech. 2021;22(3):128. doi:10.1208/s12249-021-01960-9.
36. Simões MF, Pinto RMA, Simões S. Hot-melt extrusion in the pharmaceutical industry: toward filing a new drug application. Drug Discov Today. 2019;24(9):1749-1768. doi:10.1016/j.drudis.2019.05.013.
37. Jaffar-Aghaei M, Khanipour F, Maghsoudi A, Sarvestani R, Mohammadian M, Maleki M, et al. QbD-guided pharmaceutical development of pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®. Eur J Pharm Sci. 2022;173:106171. doi:10.1016/j.ejps.2022.106171.
38. Guerra A, von Stosch M, Glassey J. Toward biotherapeutic product real-time quality monitoring. Crit Rev Biotechnol. 2019;39(3):289-305. doi:10.1080/07388551.2018.1524362.
39. Nandi U, Trivedi V, Ross SA, Douroumis D. Advances in twin-screw granulation processing. Pharmaceutics. 2021;13(5):624. doi:10.3390/pharmaceutics13050624.
40. Simões A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: an enhanced quality approach. Eur J Pharm Biopharm. 2024;195:114174. doi:10.1016/j.ejpb.2023.114174.
41. Simões A, Veiga F, Vitorino C, Figueiras A. A tutorial for developing a topical cream formulation based on the quality by design approach. J Pharm Sci. 2018;107(10):2653-2662. doi:10.1016/j.xphs.2018.06.010.
42. Grangeia HB, Silva C, Simões SP, Reis MS. Quality by design in pharmaceutical manufacturing: a systematic review of current status, challenges and future perspectives. Eur J Pharm Biopharm. 2020;147:19-37. doi:10.1016/j.ejpb.2019.12.007.
43. Rathore AS, Garcia-Aponte OF, Golabgir A, Vallejo-Diaz BM, Herwig C. Role of knowledge management in development and lifecycle management of biopharmaceuticals. Pharm Res. 2017;34(2):243-256. doi:10.1007/s11095-016-2043-9.
44. Nunavath RS, Singh MT, Jain A, Chakma M, Arivuselvam R, Azeeze MSTA. Quality by design in pharmaceuticals: a review of its impact on regulatory compliance and product quality. Drug Res (Stuttg). 2024;74(1):18-23. doi:10.1055/a-2185-4916.
45. Zagalo DM, Sousa J, Simões S. Quality by design (QbD) approach in marketing authorization procedures of non-biological complex drugs: a critical evaluation. Eur J Pharm Biopharm. 2022;178:1-24. doi:10.1016/j.ejpb.2022.07.014.
46. Duchek J, Havasi B. Analysis of particulate matter in liquid-finished dosage forms. PDA J Pharm Sci Technol. 2018;72(6):608-625. doi:10.5731/pdajpst.2017.008292.
47. Zhu Z. Intelligent information management enables quality-by-design in pharmaceutical production. Sci Rep. 2025;15(1):44201. doi:10.1038/s41598-025-27879-w.
48. Yacobi A, Shah VP, Bashaw ED, Benfeldt E, Davit B, Ganes D, et al. Current challenges in bioequivalence, quality, and novel assessment technologies for topical products. Pharm Res. 2014;31(4):837-846. doi:10.1007/s11095-013-1259-1.
49. Peraman R, Bhadraya K, Padmanabha Reddy Y. Analytical quality by design: a tool for regulatory flexibility and robust analytics. Int J Anal Chem. 2015;2015:868727. doi:10.1155/2015/868727.
50. Tomba E, Facco P, Bezzo F, Barolo M. Latent variable modeling to assist the implementation of quality-by-design paradigms in pharmaceutical development and manufacturing: a review. Int J Pharm. 2013;457(1):283-297. doi:10.1016/j.ijpharm.2013.08.074.

51. Orlandini S, Hancu G, Szabó ZI, Modroiu A, Papp LA, Gotti R, et al. New trends in the quality control of enantiomeric drugs: quality by design-compliant development of chiral capillary electrophoresis methods. Molecules. 2022;27(20):7058. doi:10.3390/molecules27207058.
52. Aucamp M, Milne M. The physical stability of drugs linked to quality-by-design (QbD) and in-process technology (PAT) perspectives. Eur J Pharm Sci. 2019;139:105057. doi:10.1016/j.ejps.2019.105057.
53. Miesle JE, Osei-Yeboah F, Pauli-Bruns A, Chen B, Manceva S, Wade JB, et al. Current approaches to design space development and regulatory applications for drug products: findings from the IQ utilization of design space for filings working group survey. Pharm Res. 2024;41(9):1775-1786. doi:10.1007/s11095-024-03765-4.
54. Lee K, Yoo W, Jeong JH. Analytical method development for 19 alkyl halides as potential genotoxic impurities by analytical quality by design. Molecules. 2022;27(14):4437. doi:10.3390/molecules27144437.
55. Morin MA, Zhang WP, Mallik D, Organ MG. Sampling and analysis in flow: the keys to smarter, more controllable, and sustainable fine-chemical manufacturing. Angew Chem Int Ed Engl. 2021;60(38):20606-20626. doi:10.1002/anie.202102009.
56. Romero-Obon M, Sancho-Ochoa V, Rouaz-El-Hajoui K, Pérez-Lozano P, Suñé-Pou M, Suñé-Negre JM, et al. Scale-agnostic models based on dimensionless quality by design as pharmaceutical development accelerator. Pharmaceuticals (Basel). 2025;18(7):1033. doi:10.3390/ph18071033.
57. Adalbert L, Kanti SPY, Jójárt-Laczkovich O, Akel H, Csóka I. Expanding quality by design principles to support 3D printed medical device development following the renewed regulatory framework in Europe. Biomedicines. 2022;10(11):2947. doi:10.3390/biomedicines10112947.
58. Yapar EA, Özdemir MN. An up-to-date screening on the tool of quality by design in pharmaceutical manufacturing. Comb Chem High Throughput Screen. 2025. doi:10.2174/0113862073388521250708101658.